ACG Case Study: Restoring Dissolution Performance to Protect First-to-File ANDA Exclusivity Window

When dissolution performance degrades on a first-to-file ANDA product, the 180-day exclusivity window, one of the most commercially significant protections in generics manufacturing, is directly at risk. ACG's published case study details how a global pharmaceutical company navigated exactly that scenario for a Fexofenadine + Pseudoephedrine extended-release MUPS tablet, a dosage form that compounds formulation complexity with the regulatory precision required under 21 CFR Part 211.

The company held first-to-file status for the ANDA, positioning it to capture the full 180-day exclusivity period ahead of subsequent generic entrants. Dissolution failure at this stage carries consequences beyond a single batch rejection: a delayed launch forfeits exclusivity days that cannot be recovered, and any out-of-specification result on an extended-release product triggers CAPA obligations, potential process revalidation, and, depending on the deviation's scope, a Prior Approval Supplement before commercial distribution can proceed.

MUPS, multiple-unit pellet system, tablets present a specific manufacturing challenge. Coating uniformity across pellet populations directly governs release kinetics, and variability in equipment performance can shift dissolution profiles outside validated design space without triggering upstream in-process alerts. For QA directors overseeing extended-release lines, the ACG case illustrates how equipment-level intervention, rather than formulation reformulation, can restore a dissolution profile within the existing validated process, preserving the regulatory package already submitted.

The process validation read is relevant here: any corrective action that alters a critical process parameter or critical quality attribute boundary on an approved ANDA requires careful change-control assessment against the original submission. Maintaining dissolution performance through equipment optimisation, where the process itself remains within its validated range, avoids that regulatory exposure and keeps the launch timeline intact.

For plant heads managing generics pipelines with first-to-file assets, the case reinforces that dissolution assurance is not solely a QC release function, it is a supply-chain and competitive-position issue that warrants upstream process monitoring proportionate to the exclusivity value at stake.

The full case study, including equipment findings and corrective measures, is available via ACG's resource library as a reference for teams managing extended-release MUPS lines ahead of ANDA launches.

Source: ACG via acg-world.com, 15 May 2026.